In recognition of the growing popularity and importance of mobile software applications that diagnose, track or treat disease, Japan is considering making the use of such apps eligible for reimbursement by its government health insurance system. The question of how and whether... Read More
The cost of the majority of pharmaceuticals sold in Japan will undergo major revisions April 1, when the Ministry of Health, Labor and Welfare (MHLW) sets new prices on more than 69% of drugs marketed in the country. The revisions mean the... Read More
The combination of a relatively low–cost workforce and increasingly reliable quality and ethical standards is turning the Asia-Pacific region into a hub for clinical trials. With pharmaceutical firms under growing pressure to provide innovative new products at reasonable prices, the region is becoming more... Read More
The global medical robotics market is booming, and the Asia Pacific region is expected to experience significant growth over the next 5 years, at a CAGR of 23.32%, according to a report published by Market Data Forecast. The market growth is driven by several factors such... Read More
Two years after Japan began employing a cost-effectiveness evaluation system to determine the efficiency and allocation of health resources, it is preparing for the first time to adjust prices of pharmaceuticals and medical devices based on such assessments. Japan’s Central Social Insurance... Read More
A host of rehabilitative technology companies are entering the Asian market in force, driven by the needs of the region’s aging population for exercise and rehab equipment to combat immobility, muscular atrophy, and the epidemics of heart disease, hypertension, stroke, osteoarthritis, and... Read More
A decades-long push by Japan to spur innovation in its pharmaceutical industry is expected to get new life this year, with government health agencies planning to release by this summer a new set of goals for speeding clinical trials and encouraging the... Read More
In a push to speed drug approval times amid the coronavirus pandemic, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is finalizing plans to permit drug companies to supplement or replace their own clinical trials with data from patients who have taken the... Read More
China, Korea, Taiwan, and Japan are rapidly becoming world leaders in cell and gene therapy research and innovation, fueled by significant public and private investment and streamlined regulations that are spurring breakthroughs in the field. All three countries have long been leaders... Read More
Globally, there has been a trend toward using more real-world data in the development of drugs and devices. Japan’s MHLW is also taking note and has drafted 2 new guidelines – 1. A basic policy on using registry data in registration submissions... Read More